|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM336830491 |
003 |
DE-627 |
005 |
20231225233031.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2022.108955
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1122.xml
|
035 |
|
|
|a (DE-627)NLM336830491
|
035 |
|
|
|a (NLM)35150919
|
035 |
|
|
|a (PII)S1521-6616(22)00035-3
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Morita, Atsushi
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Time course of peripheral immunophenotypes of multisystem inflammatory syndrome in children
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 16.03.2022
|
500 |
|
|
|a Date Revised 21.12.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
520 |
|
|
|a The etiology of multiple inflammatory syndrome in children (MIS-C) remains poorly understood. As clues to elucidate the pathogenic condition, several characteristic peripheral immunophenotypes have been reported in MIS-C. However, no report has demonstrated the time course of the peripheral immunophenotype along with the clinical course in the same patient. Herein, we clarified the immunological characteristics of a Japanese patient with MIS-C. There was an initial cytokine storm followed by T-cell activation, especially of CD8+ T cells, with the expansion of T-cell receptor Vβ 21.3-expressing cells, which suggests superantigen-mediated T-cell activation. In addition, we also found an increase in IgG-producing cells (plasmablasts and switched memory B cells), which were accompanied by elevated serum levels of anti-SARS-CoV-2 spike antigen-specific IgG antibodies. These time course of peripheral immunophenotypes support that immunological activation against SARS-CoV-2 spike protein plays a central role in the etiology of MIS-C
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Antibody
|
650 |
|
4 |
|a IgG
|
650 |
|
4 |
|a MIS-C
|
650 |
|
4 |
|a SARS-CoV-2
|
650 |
|
4 |
|a Spike protein
|
650 |
|
4 |
|a Vβ 21.3
|
650 |
|
7 |
|a Spike Glycoprotein, Coronavirus
|2 NLM
|
650 |
|
7 |
|a spike protein, SARS-CoV-2
|2 NLM
|
700 |
1 |
|
|a Hosaka, Sho
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Imagawa, Kazuo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ishiodori, Takumi
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Nozaki, Yoshihiro
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Murakami, Takashi
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Takada, Hidetoshi
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 236(2022) vom: 06. März, Seite 108955
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:236
|g year:2022
|g day:06
|g month:03
|g pages:108955
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108955
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 236
|j 2022
|b 06
|c 03
|h 108955
|